What targets should lipid-modulating therapy achieve to optimise the prevention of coronary heart disease?

Atherosclerosis

Volumn 131, Issue 1, 1997, Pages 1-5

  Thompson, Gilbert R ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Angiography; Cardiovascular events; High density lipoprotein; Low density lipoprotein; Triglyceride

Indexed keywords

ANTILIPEMIC AGENT; BEZAFIBRATE; COLESTIPOL; COLESTYRAMINE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ANGIOCARDIOGRAPHY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MORTALITY; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT PLANNING; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0030910367     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(97)06084-X     Document Type: Article

References (26)

1. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 1992;33:1569.
2. Lovastatin Study Groups I through IV. Lovastatin 5-year safety and efficacy study. Arch Intern Med 1993;153:1079.
3. Brown G, Albers JJ, Fisher LD et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289.
4. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990;264:3007.
5. Sacks FM, Pasternak RC, Gibson CM, Rosner B, Stone PH. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Lancet 1994;344:1182.
6. Thompson GR, Maher VMG, Matthews S et al. The Familial Hypercholesterolaemia Regression Study: a randomised trial of LDL apheresis. Lancet 1995;345:811.
7. Blankenhorn DH, Azen SP, Kramsch DM et al. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 1993;119:969.
8. Waters D, Higginson L, Gladstone P et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. Circulation 1994;89:959.
9. MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 1994;344:633.
10. Pitt B, Mancini GB, Ellis SG, Rosman HS, Park JS, McGovern ME. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC-I): reduction in atherosclerosis progression and clinical events. JACC 1995;26:1133.
11. Thompson GR, Hollyer J, Waters DD. Percentage change rather than plasma level of LDL-cholesterol determines therapeutic response in coronary heart disease. Curr Opin Lipidol 1995; 6:386 (Published erratum in: Curr Opin Lipidol 1996;7(1)).
12. Thompson GR. Angiographic trials of lipid-lowering therapy: end of an era? Br Heart J 1995;74:343.
13. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301.
14. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383.
15. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001.
16. Jukema JW, Bruschke AV, van Boven AJ et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995;91:2528.
17. Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 1995;345:1274.
18. European Atherosclerosis Society International Task Force for Prevention of Coronary Heart Disease. Prevention of coronary heart disease. Scientific background and new clinical guidelines. Nutr Metab Cardiovasc Dis 1992;2:113.
19. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993;269:3015.
20. Frick MH, Elo O, Haapa K et al. Primary prevention trial with gemfibrozil in middle-aged men with dyslipidaemia. N Engl J Med 1987;317:1237.
21. Manninen V, Tenkanen L, Koskinen P et al. Joint effects of serum triglycede and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Circulation 1992;85:37.
22. Ericsson C-G, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male post-infarction patients. Lancet 1996;347:849.
23. Sacks FM, Wun C-C., Cole TG et al. The influence of baseline lipid levels on reduction in coronary events by pravastatin: the Cholesterol and Recurrent Events Trial. Circulation 1996;94;Suppl 1.
24. Nawrocki JW, Weiss SR, Davidson MH et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995;15:678.
25. Bakker-Arkema RG, Davidson MH, Goldstein RJ et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996;275:128.
26. Thompson GR, Naoumova RP, Watts GF. Role of cholesterol in regulating apolipoprotein B secretion by the liver. J Lipid Res 1996;37:439.